DB:7AY

Stock Analysis Report

Executive Summary

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies.


Snowflake Analysis

Mediocre balance sheet with moderate growth potential.

Share Price & News

How has Actinium Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7AY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.6%

7AY

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-55.7%

7AY

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 7AY underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 7AY underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

7AYIndustryMarket
7 Day2.6%11.3%7.1%
30 Day-23.3%-8.0%-20.0%
90 Day-14.8%-22.7%-26.1%
1 Year-55.7%-55.7%-4.9%-5.1%-15.0%-17.5%
3 Year-89.1%-89.1%17.7%16.4%-18.8%-25.8%
5 Year-93.4%-93.4%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Actinium Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Actinium Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7AY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 7AY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 7AY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 7AY is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7AY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7AY is good value based on its PB Ratio (3.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Actinium Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

65.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7AY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 7AY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 7AY's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if 7AY's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 7AY's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 7AY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Actinium Pharmaceuticals performed over the past 5 years?

-3.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7AY is currently unprofitable.

Growing Profit Margin: 7AY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 7AY is unprofitable, and losses have increased over the past 5 years at a rate of -3.1% per year.

Accelerating Growth: Unable to compare 7AY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7AY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 7AY has a negative Return on Equity (-237.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Actinium Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 7AY's short term assets ($14.6M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: 7AY's short term assets ($14.6M) exceed its long term liabilities ($841.1K).


Debt to Equity History and Analysis

Debt Level: 7AY's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: 7AY's debt to equity ratio has increased from 0.1% to 0.3% over the past 5 years.


Balance Sheet

Inventory Level: 7AY has a low level of unsold assets or inventory.

Debt Coverage by Assets: 7AY's debt is covered by short term assets (assets are 574.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7AY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 7AY has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.4% each year


Next Steps

Dividend

What is Actinium Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7AY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 7AY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7AY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7AY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7AY's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Sandesh Seth (55yo)

2.75s

Tenure

US$1,374,253

Compensation

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK)  ...


CEO Compensation Analysis

Compensation vs Market: Sandesh's total compensation ($USD1.37M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Sandesh's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sandesh Seth
Chairman & CEO2.75yrsUS$1.37m0.098% $28.7k
Steven O'Loughlin
Principal Financial & Accounting Officer2.83yrsUS$505.55k0.022% $6.3k
Dale Ludwig
Chief Scientific Officer2.17yrsUS$424.70k0.0061% $1.8k
Mark Berger
Chief Medical Officer3.17yrsUS$612.31k0.014% $4.0k
David Gould
Senior Vice President of Corporate Development & Corporate Affairsno datano datano data
Bernie Cunningham
Executive Director of Clinical Supply Chain & Logistics and CMC Project Management3.42yrsno datano data
Qing Liang
VP & Head of Radiation Sciences1.17yrsno datano data
Cynthia Pussinen
Executive Vice President of Technical Operations & Supply Chain1.17yrsno datano data
Robert Daly
VP & Head of Clinical Operations1.5yrsno datano data
Mamata Gokhale
VP & Global Head of Regulatory Affairs1yrno datano data

2.2yrs

Average Tenure

56yo

Average Age

Experienced Management: 7AY's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sandesh Seth
Chairman & CEO2.75yrsUS$1.37m0.098% $28.7k
Richard Steinhart
Independent Director6.33yrsUS$107.29k0.0058% $1.7k
David Scheinberg
Member of Clinical Advisory Boardno datano datano data
Richard Wahl
Member of Clinical Advisory Boardno datano datano data
Ajit Shetty
Independent Director3yrsUS$99.69k0.014% $4.0k
C. Nicholson
Lead Independent Director2.5yrsUS$104.69k0.0061% $1.8k
Joseph Jurcic
Chairman of Clinical Advisory Boardno datano datano data
Elihu Estey
Member of Clinical Advisory Boardno datano datano data
John Pagel
Chairman of Scientific Advisory Board & Member of Clinical Advisory Boardno datano datano data
Alexander Perl
Member of Clinical Advisory Boardno datano datano data

4.7yrs

Average Tenure

63yo

Average Age

Experienced Board: 7AY's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.3%.


Top Shareholders

Company Information

Actinium Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Actinium Pharmaceuticals, Inc.
  • Ticker: 7AY
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$32.446m
  • Listing Market Cap: US$29.263m
  • Shares outstanding: 164.70m
  • Website: https://www.actiniumpharma.com

Number of Employees


Location

  • Actinium Pharmaceuticals, Inc.
  • 275 Madison Avenue
  • 7th Floor
  • New York
  • New York
  • 10016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATNMAMEX (NYSE MKT LLC)YesNew Common StockUSUSDDec 2012
7AYDB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2012

Biography

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 22:52
End of Day Share Price2020/03/27 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.